After finishing at $5.95 in the prior trading day, Fate Therapeutics Inc (NASDAQ: FATE) closed at $5.77, down -3.03%. On the day, 1837646 shares were traded.
Ratios:
Our goal is to gain a better understanding of FATE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.48 and its Current Ratio is at 8.48. In the meantime, Its Debt-to-Equity ratio is 0.28 whereas as Long-Term Debt/Eq ratio is at 0.26.
On January 24, 2023, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $115 to $7.
Wedbush Downgraded its Outperform to Neutral on January 06, 2023, whereas the target price for the stock was revised from $42 to $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 04 ’24 when Dulac Edward J III sold 2,447 shares for $7.77 per share. The transaction valued at 19,013 led to the insider holds 101,479 shares of the business.
Dulac Edward J III sold 1,849 shares of FATE for $9,245 on Jan 29 ’24. The Chief Financial Officer now owns 103,926 shares after completing the transaction at $5.00 per share. On Jan 09 ’24, another insider, Wolchko J Scott, who serves as the President and CEO of the company, sold 14,391 shares for $4.37 each. As a result, the insider received 62,889 and left with 371,248 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 9.01 while its Price-to-Book (P/B) ratio in mrq is 1.54.
Stock Price History:
Over the past 52 weeks, FATE has reached a high of $8.83, while it has fallen to a 52-week low of $1.63.
Shares Statistics:
A total of 98.63M shares are outstanding, with a floating share count of 86.74M. Insiders hold about 12.59% of the company’s shares, while institutions hold 103.93% stake in the company.
Earnings Estimates
Its stock is currently analyzed by FAT Brands Inc. different market analysts. The consensus estimate for the next quarter is $5.77, with high estimates of $0.67 and low estimates of $30.60.
